ClinicalTrials.gg
Status unknownNCT05356624Updated May 2, 2022

Mobilization With Movement Versus Soft Tissue Mobilization in Patients With De Quervain Tenosynovitis

An interventional study of Mulligan Mobilization and Soft Tissue Mobilization in De Quervain Syndrome, sponsored by Riphah International University. Status unknown at 1 site in Pakistan. Open to participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-02.

Sponsored by Riphah International University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
All
01

Study summary

this study will investigate the effects of mobilization with movement in addition to soft tissue mobilization on pain and range of motion in patients suffering from De Quervain Tenosynovitis.

Read the detailed description

De quervain tenosynovitis also known as stenosing tenosynovitis is a condition which occur when tendons at the base of thumb pinched and become irritated. Several treatment options are available like ultrasound, Graston therapy, thrust or non-thrust manipulation, mobilization with movement, soft tissue mobilization but this study focus on 2 treatments to improve malalignment of the joint and also reduce pain. First treatment is mobilization with movement in which passive accessory mobilization from therapist while active mobility is performed by patient. Second technique is soft tissue mobilization in which passive glides are applied. The purpose of study is to make comparison between mobilization with movement and soft tissue mobilization.

02

Conditions studied

  • De Quervain Syndrome

Keywords

  • de quervains tenosynovitis
  • pain
  • manual therapy
  • ROM
03

In context

De Quervain Disease

30 studies on the registry are indexed under De Quervain Disease; 7 are open to participants now.

This study's planned enrollment of 30 is below the median of 55 across 26 interventional studies indexed under De Quervain Disease.

Browse De Quervain Disease studies →

Lead sponsor

Riphah International University is the lead sponsor of 2,193 studies on the registry; 650 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female

    • 20 to 50 years
    • Subjects with pain in base of thumb (9)
    • Subject with positive fienklstein test

Exclusion criteria

Exclusion Criteria:

  • History of radiculopathy

    • History of systemic illness
    • History of connective tissue disorder
    • Rheumatoid arthritis
    • History of hand or wrist injury or acute trauma
    • Subject with negative fienklstein test
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Mulligan Mobilization

    Mobilization with movement (3 sets per 10 repetitions).

    Other: Mulligan Mobilization

  • Experimental
    Soft tissue mobilization

    Soft tissue mobilization (3 sets per 10 repetitions)

    Other: Soft Tissue Mobilization

Interventions

  • OtherMulligan Mobilization

    It is technique in which passive mobilization is applied by therapist to improve the normal position and by holding the passive glide active movement in restricted direction of motion to reduce pain or improve range of motion or function. A total of 3 sets of 10 repetition three times a week on alternate days for 6 week

  • OtherSoft Tissue Mobilization

    in this technique for joint the passive glides are applied, for CMC joint mobilization patient hand is rest on table. The therapist grasp trapezium with one hand and 1st metacarpal between index and thumb of other hand to apply glide. A total of 3 sets of 10 repetition three times a week on alternate days for 6 weeks.

06

What researchers measure

Primary outcomes

  1. Visual analogue scale

    It is a 100 mm scale drawn on a paper to determine the level or intensity of pain in range of (0 to 10)

    Time frame: 3 months

  2. Goniometry

    The science of measuring the joint ranges in each plane of the joint is called goniometry. Goniometer is a device that measures an angle or permits the rotation of an object to a definite position. Neck flexion, extension, side bending and rotation will be assessed

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
  • Aziz Bhatti Shaheed hospital
    Gujrat, Punjab 38000, Pakistan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Aug 2022, 4 months after the start.

Of 16 interventional studies with no phase under De Quervain Disease, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 28. This study's planned 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2022
First posted
May 2, 2022
StartActual
Apr 15, 2022
Primary completionEst.
Aug 15, 2022
CompletionEst.
Sep 15, 2022
Last update
May 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05356624
Responsible party
Sponsor
First posted
May 2, 2022
Start date
Apr 15, 2022
Primary completion
Aug 15, 2022 (estimated)
Completion
Sep 15, 2022 (estimated)
Last update
May 2, 2022

Study contacts

Nosheen Manzoor, MS-OMPT
Contact
nosheen.manzoor@riphahfsd.edu.pk
03236877879
Nosheen Manzoor, MS-OMPT
principal investigator · Riphah International University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion